Saxonov Serge 4
4 · 10x Genomics, Inc. · Filed May 27, 2026
Research Summary
AI-generated summary of this filing
10x Genomics (TXG) CEO Serge Saxonov Sells Shares
What Happened
Serge Saxonov, CEO of 10x Genomics (TXG), reported open-market sales totaling 28,893 shares for aggregate proceeds of about $709,057. The filings show two dispositions: 18,175 shares sold on 2026-05-22 at $24.44 each ($444,224) and 10,718 shares sold on 2026-05-26 at a weighted average price of $24.71 each ($264,833). These sales were reported as dispositions (S), not purchases.
Key Details
- Transaction dates and prices:
- 2026-05-22: 18,175 shares @ $24.44 = $444,224
- 2026-05-26: 10,718 shares @ weighted avg $24.71 = $264,833 (executed in multiple trades at prices from $24.45 to $24.88)
- Total sold: 28,893 shares for ~$709,057.
- Purpose: Shares were sold to cover tax withholding obligations related to restricted stock unit vesting (footnote F1).
- 10b5-1 plan: At least one transaction was effected under the reporting person's Rule 10b5-1 trading plan adopted Nov 29, 2025 (footnote F2).
- Trust holdings: Some shares are held in trusts (Andromeda Trust, Y/S Descendants' Trust, Y/S Pot Trust) for which Saxonov serves as trustee (footnotes F4–F6).
- Shares owned after the transaction: Not disclosed in the provided excerpt.
- Filing timeliness: Form 4 was filed 2026-05-27 for transactions dated 2026-05-22 and 2026-05-26; no late-filing flag is indicated in the provided data.
Context
These were sales (not purchases) and reported as routine transactions to satisfy tax-withholding on RSU vesting. Sales made under a pre-established 10b5-1 plan and tax-related dispositions are common and do not, by themselves, indicate the insider’s view of the company’s prospects.
Insider Transaction Report
- Sale
Class A Common Stock
[F1]2026-05-22$24.44/sh−18,175$444,224→ 1,149,098 total - Sale
Class A Common Stock
[F2][F3]2026-05-26$24.71/sh−10,718$264,833→ 1,138,380 total
- 27(indirect: See footnote)
Class A Common Stock
[F4] - 213,250(indirect: See footnote)
Class A Common Stock
[F5] - 71,644(indirect: See footnote)
Class A Common Stock
[F6]
Footnotes (6)
- [F1]The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
- [F2]The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
- [F3]This transaction was executed in multiple trades at prices ranging from $24.45 to $24.88, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F4]The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
- [F5]The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
- [F6]The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.